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cellular signaling cascades. They contain highly homologous catalytic domains and flexible C-terminal hypervariable regions
(HVRs) that differ across Ras isoforms. KRAS is among the most frequently mutated oncogenes in human tumors. Surprisingly,
we found that the C-terminal HVR of K-Ras4B, thought to minimally impact the catalytic domain, directly interacts with the active
site of the protein. The interaction is almost 100-fold tighter with the GDP-bound than the GTP-bound protein. HVR binding in-
terferes with Ras-Raf interaction, modulates binding to phospholipids, and slightly slows down nucleotide exchange. The data
indicate that contrary to previously suggested models of K-Ras4B signaling, HVR plays essential roles in regulation of signaling.
High affinity binding of short peptide analogs of HVR to K-Ras active site suggests that targeting this surface with inhibitory syn-
thetic molecules for the therapy of KRAS-dependent tumors is feasible.INTRODUCTIONK-Ras4B is a ubiquitous p21 GTPase that controls cell sur-
vival and proliferation (1). KRAS is frequently mutated in
cancers of epithelial origin, including lung, colorectal, and
pancreatic malignancies (2-4). Oncogenic mutations in
K-Ras impair GTP hydrolysis (5) and lead to constitutive
activation of signaling (6,7). Despite the central role of
K-Ras in oncogenesis and widespread efforts to develop
Ras-directed anti-cancer therapeutics (8-11), no selective,
specific inhibitor of K-Ras is available for clinical use
(12-14). This is primarily because its catalytic domain lacks
pockets for high affinity small molecule binders (15,16).
There are two alternative K-Ras mRNA splice variants—
K-Ras4A and K-Ras4B. They differ in their 25-amino-acid-
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0006-3495/15/12/2602/12where the fourth exon of K-Ras4B encodes a lysine-rich re-
gion (17,18). Apart from distinct HVRs, Ras proteins are
also differentially posttranslationally modified in their
HVRs (19). As a result, the differences in the binding of
Ras proteins to their binding partners, or the membrane,
could be attributed to their HVRs and the different post-
translational modifications (20). Recent studies clearly
demonstrate that each Ras isoform functions in a unique
way, differing from other Ras proteins in normal physiolog-
ical processes as well as in pathogenesis (21,22). The posi-
tively charged HVR and the posttranslational modifications
target K-Ras4B to the plasma membrane, where it initiates
signaling events (23). X-ray and nuclear magnetic reso-
nance (NMR) structural studies point to a highly flexible
C-terminal tail (24). NMR chemical shift appears to be a
useful tool to obtain the preferred conformational states
for an unstructured linker (25).
Our studies indicate that the K-Ras4B HVR interacts
with the catalytic domain extensively when the catalytic
domain is GDP-loaded. However, when the GTP replaces
GDP, the HVR has minimal interaction with the catalytic
domain, indicating that the HVR is sequestered in the
GDP-bound state and released in the GTP-bound state.
Remarkably, the interaction surface identified by NMR
and modeling overlaps significantly with those involved
in some effectors, such as Raf and PI3K binding. Further,
the interaction interface is similar, involving Switch I and
b2 regions (see the Ras domain and functional sites shown
in Fig. 1). Our data indicates that the HVR interaction ishttp://dx.doi.org/10.1016/j.bpj.2015.09.034
FIGURE 1 K-Ras4B sequence and structures.
(A) The sequence of the K-Ras4B protein with
each domain structure embedded in a cartoon rep-
resentation. In the sequence are hydrophobic
(black), polar/glycine (green), positively charged
(blue), and negatively charged (red) residues. The
same colors were used in the ribbon representation,
except for the hydrophobic residues (white). Crys-
tal structures of K-Ras4B proteins are in (B) GDP-
bound (PDB: 4EPT) and (C) GTP-bound (PDB:
3GFT) states. The structures were generated for
wild-type sequences with the nucleotides modified
from the crystalized mutant conformations. In the
protein structures, the a-helix (gray) and b-sheet
(yellow) secondary structures are shown. Func-
tional regions are marked on the structures. To
see this figure in color, go online.
K-Ras HVR Binding to Ras Active Site 2603important in regulation of Ras function. Coupled with
membrane interaction and a possible role in orienting and
linking membrane-anchored Ras molecules in nanoclus-
ters, HVR emerges as an important player in Ras function
in the cell.MATERIALS AND METHODS
Peptide synthesis
The peptides were synthesized on a Liberty Microwave peptide synthe-
sizer (CEM, Matthews, NC) using Fmoc chemistry. To avoid oxidation,
Met residues in the sequence of HVR have been substituted by isosteric
norleucine. The peptides were cleaved from the resin and deprotected
with a mixture of 90.0% (v/v) TFA (trifluoroacetic acid) with 2.5% water,
2.5% triisopropyl-silane, and 5% thioanisol. The dried crude peptide was
dissolved in DMSO (dimethyl sulfoxide) and purified on a preparative
(25  250 mm) Atlantis C18 reverse phase column (Agilent Technologies,
Santa Clara, CA) in a 90 min gradient of 0.1% (v/v) TFA in water and
0.1% TFA in acetonitrile, with a 10 mL/min flow rate. The fractions con-
taining peptides were analyzed on a model No. 1100 LC/MS spectrometer
(Agilent Technologies) with the use of a Zorbax 300SB-C3 Poroshell col-
umn (Agilent Technologies) and a gradient of 5% acetic acid in water and
acetonitrile. Fractions that were >95% pure were combined and freeze-
dried. For generation of palmitoylated peptide kR-4B-1, Fmoc-Lys
(ε-DDE) was coupled manually to PAL AM resin. The DDE group wasremoved by incubation with an imidazol/hydroxylamine mixture as
described in Johannessen et al. (26). Ten-fold molar excess of palmitic
acid was dissolved in methylene chloride/n-methylpyrrolidone mixture
(1:1), mixed with equimolar amounts of HCTU (1H-Benzotriazolium
1-[bis(dimethylamino)methylene]-5chloro-,hexafluorophosphate (1-),3-ox-
ide) and diisopropylethylamine and added to the resin. After overnight in-
cubation, nonreacted amino groups were blocked with acetic anhydride;
the resin was washed with n-methylpyrrolidone and methylene chloride
and dried under the hood. The rest of the peptide synthesis was performed
on the synthesizer as described above.K-Ras labeling with fluorescein
A quantity of 1.6 mg fluoresceine maleimide (Santa Cruz Biotechnology,
Santa Cruz, CA) was dissolved in 25 mL DMSO. Five microliters were
diluted in 10 mL buffer. The resulting solution was slowly added to 400 mL
of 75mMGDPorGTP-g-S-loadedK-Ras solution in 100mMHEPES buffer
pH 6.5 containing 5 mMMgCl2 and 50 mMNaCl. Mixtures were incubated
overnight at 4C and filtered through NAP-5 column (GE Healthcare Life
Sciences, Marlborough, MA) equilibrated with the reaction buffer. LC/MS
showed no traces of the maleimide and complete labeling of intact K-Ras.Microscale thermophoresis
For the microscale thermophoresis (MST) studies we have prepared 16
twofold serial dilutions of peptides starting from 30 mM. Titration seriesBiophysical Journal 109(12) 2602–2613
2604 Chavan et al.have been prepared that contained 15 mL of 80 nM fluorescein-labeled
K-Ras and 15 mL of peptides solution of varying concentrations. Final
buffer composition included 20 mM HEPES pH 7.0, 1 mM MgCl2,
0.5 mM TCEP-HCl, 0.5 mM NaN3, and 10 mM either GDP or GTP-g-S
(Ras buffer) and 0.05% TWEEN-20 for nonlipidated HVR analogs. Lipi-
dated HVR analog kR-4B-1 was dissolved in Ras buffer containing
nanodisks composed of 95% DPPC (1,2-dipalmitoyl-sn-glycero-3-phos-
phocholine), and 5% DPPE (1,2-dihexadecanoyl-sn-glycero-3-phosphoe-
thanolamine). Nanodisks have been prepared as described in Abraham
et al. (27). All measurements were taken in standard treated capillaries
on a Monolith NT.115 instrument (NanoTemper Technologies, Munich,
Germany) using 60% infrared laser power and an LED excitation source
with l ¼ 470 nm. NanoTemper Analysis 1.2.20 software was used to fit
the data and to determine the KD values.Protein preparations
Protein preparation was carried out according to our previously published
protocol (27). K-Ras4B cDNA (full-length and catalytic domain) from In-
vitrogen, Carlsbad, CA was cloned into the pET42a vector (Novagen,
Madison, WI). The restriction sites used were NdeI and XhoI. A His-tag
was introduced to aid protein purification. The plasmid was transformed
into BL21AI cells and the cells were grown in M9 medium (28) with
shaking at 250 rpm. K-Ras4B is generally expressed by Escherichia coli
in the inclusion bodies. To increase the fraction of the correctly folded
and soluble protein, we stimulated production of osmotic shock chaper-
ones by adding 0.4 M NaCl to the expression media as previously
described in Abraham et al. (27). The cells were grown at 37C until their
OD600 reached 0.6. Then, the expression of K-Ras4B was induced with
0.2 mM IPTG, 0.2% arabinose, and 2% ethanol. The cells were grown
thereon for 24 h at 18C with shaking at 250 rpm. The cells were har-
vested by centrifuging and the pellets were stored at 80C. The pellets
were thawed at room temperature before lysis. Lysis was carried out using
the B-PER bacterial extraction reagent (Pierce Chemical, Rockford, IL)
with addition of 10 mM MgCl2, 50 mg/mL DNaseI, 2 mM PMSF (phenyl-
methanesulfonyl fluoride), 1–2 tablets of EDTA-free complete (Hoffmann-
La Roche, Basel, Switzerland), and 10 mg of lysozyme. Pellets were kept
in the lysis buffer with shaking at 200 rpm for 40 min at room tempera-
ture. The lysate was centrifuged at 14,000 g at 4C and the supernatant
was collected. For extracting the protein from the insoluble fraction, the
pellets were resuspended in 10 mM Tris-HCl pH 7.6, 20 mM Na-citrate,
50 mM KCl, 5 mM MgCl2, 0.1 mM GDP, and 2 mM b-mercaptoethanol.
The protein pellets were kept in this buffer with shaking at 200 rpm for
40 min at room temperature. The suspension was centrifuged similarly
to the first lysate and the supernatant was collected. The cell debris was
discarded. The first and second extraction fractions were dialyzed sepa-
rately against 1 binding buffer (Novagen) containing 10% glycerol for
~12 h. Both supernatants were incubated with the His-Bind resin for
3 h. Washing was done with the His-Bind Wash buffer and elution was
carried out using a gradient from 30 mM to 1 M imidazole. The purity
of the protein was assessed using sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and mass spectrometry. Pure fractions were dialyzed
against 25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5% glycerol, 10 mM
MgCl2, 1 mM EDTA, and 1 mM b-mercaptoethanol. For nucleotide
loading into the protein, 20 mL of 0.5 M EDTA per 1 mL of protein solu-
tion was added and GTP-g-S or GDP was added to a final concentration of
1 mM. This mixture was incubated at 30C for 30 min. The reaction was
stopped by adding 100 mM MgCl2. The buffer was changed to include the
Tris-citrate buffer (50 mM Tris-citrate, pH 6.5, 50 mM NaCl, 5 mM
MgCl2, 0.01 mM GDP, and 10 mM b-mercaptoethanol). The efficiency
of nucleotide exchange was checked by running nucleotides dissociated
from K-Ras4B by EDTA (ethylenediaminetetraacetic acid) treatment on
a C18 HPLC column. The GTPase hydrolysis assay was carried out
to confirm activity of protein. This has been previously reported by our
group (27).Biophysical Journal 109(12) 2602–2613NMR experiments
Avance Spectrometers (Bruker Daltonics, Billerica, MA), 900 Mhz and 600
Mhz, equipped with a cryogenic probe, were used for measuring 1H-15N
HSQC NMR spectra. The proteins were dissolved in 50 mM Tris-citrate,
pH 6.5, 50 mM NaCl, 5 mM MgCl2, 10 mM b-mercaptoethanol, 10 mM
CaCl2, and 10%
2H2O for conducting the experiments. All experiments
were carried out at 25C. NMRPipe software (29) was used for processing
and analyzing the data. The chemical shift assignments were taken from the
BMRB database (http://www.bmrb.wisc.edu) using the BMRB ID: 17785
and 18529 numbers. The assignments for the HVR were made using
HNCA, HNCACB, and CBCACOHN experiments. Lysine to alanine mu-
tants were used to resolve ambiguities in lysine assignments in the HVR.
The experiments on GTP-g-S-loaded K-Ras4B were carried out as soon
as possible after loading with the GTP-g-S nucleotide isoforms to ensure
that the nucleotide was not hydrolyzed. The mean chemical shift difference
was calculated using the following formula:
DdNH ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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Chemical shift perturbations (CSPs) higher than the sum of the average
and 1 SD were considered to be statistically significant. The concentrationsof proteins used in each experiment are mentioned in the figure legends.Molecular dynamics simulations
Two Ras crystal structures (PDB: 4EPT and 3GFT) were used to model the
full-length K-Ras4B protein (Fig. 1). The former is GDP-loaded with a
point mutation C118S. The latter is GppNHp (a GTP analog)-loaded,
with a point mutation Q61H.We extracted the coordinates from both crystal
structures and replaced the mutants with the wild-type residues. GppNHp
was converted to GTP. The coordinates of Mg2þ at the active site were
also extracted. Then, we constructed an HVR chain and covalently con-
nected it to H166 with the CHARMM program (30). Interactive molecular
dynamics (MD) analysis (31) in a molecular visualization program (VMD)
(32) with the NAMD (33) code was used to relocate the HVR onto the
catalytic domain based on the NMR CSP results and to preequilibrate the
proteins for 5 ns. Four different initial configurations for each GDP- and
GTP-bound state of K-Ras4B were generated. The initial configurations
of the K-Ras4B proteins were solvated by the modified TIP3P water model
(34) and gradually relaxed with the proteins held rigid. The unit cell dimen-
sion is 120 A˚3 containing almost 180,000 atoms. The systems also contain
50 Naþ, and 5 Mg2þ, and 61 Cl for the GDP-bound K-Ras4B, but a quan-
tity of 60 Cl was added to the GTP-bound protein systems. In the preequi-
librium stages, a series of minimization and dynamics cycles were
performed with the harmonically restrained proteins. At the final preequili-
brium stage, the peptide was gradually relaxed by removing the harmonic
restraints through dynamic cycles with the full Ewald electrostatics calcu-
lation. In the production runs, the Langevin temperature control was used to
maintain the constant temperature at 310 K. Nose´-Hoover Langevin piston
pressure control was used to sustain the pressure at 1 atm. For production
runs of 100 ns, the NAMD code (33) was employed on the Biowulf cluster
at the National Institutes of Health (Bethesda, MD). Averages were taken
after 30 ns, discarding initial transient trajectories. Analysis was performed
with the CHARMM programming package (30).Raf-1 Ras binding domain assay
The Raf-1 Ras-binding-domain (RBD) assay was carried out according to
the protocol published by Chavan et al. (35) using Raf-1 RBD agarose
beads from Millipore (Billerica, MA). The assay was done on GDP- and
GTP-bound forms of K-Ras4B in its full length and truncated versions or
K-Ras HVR Binding to Ras Active Site 2605lysates of H358 lung cancer cells grown in 25 mm dishes and treated with
an HVR analog for different time intervals. ImageJ software was used for
analyzing the K-Ras4B amounts on Western blots. The ratio of measured
band intensities of K-Ras4B1-166 pulled down with Raf-1 RBD beads to
K-Ras4B1-166 alone was normalized to a 100%. The full-length protein
band intensities were treated in a manner similar to those of K-Ras4B1-166.SOS1-catalyzed nucleotide exchange
For the experiment, 40 mL of 0.6 mM K-Ras4B1-166 loaded with MANT-
GDP (Invitrogen) (0.3 mM final concentration) in 20 mM HEPES buffer
pH 7.0 containing 100 mM NaCl, 0.5mM TCEP (tris(2-carboxyethyl)phos-
phine), 5 mM MgCl2, 0.5 mM NaN3, and 0.1 mg/mL BSA (bovine serum
albumin) was added to the wells of a black low-binding 384-well plate
(Cat. No. 3575; Corning, Rochester, NY). After addition of 10 mL stock so-
lution of peptide or buffer, the reaction was started by addition of 10 mL of
SOS1 (Cytoskeleton, Denver, CO) solution with the help of a multichannel
pipet to provide final 0.6 mM concentration of the guanine nucleotide ex-
change factor (GEF). Recording of the fluorescence on a FLUOStar fluores-
cence plate reader (BMG LABTECH, Cary, NC) started ~10 s after SOS1
addition. The measurements continued every 20 s for 40 min and utilized
370 nm excitation (bandwidth 2–5 nm) and 450 nm emission filters. Each
experiment was repeated independently five times. Half-lives were deter-
mined using single-exponential decay fit in Prism software.RESULTS
The HVR interacts with the catalytic domain of
K-Ras4B in the GDP-bound state and is released
in the GTP-bound state
We previously found that the interaction of calmodulin with
the HVR of K-Ras4B is inhibited upon GDP binding (36).
This observation led us to hypothesize that the catalytic
domain of K-Ras4B in its GDP-bound state might sequester
the HVR, making it unavailable for protein-protein interac-
tions. To test the hypothesis that HVR interacts with the rest
of K-Ras4B and nucleotide binding plays a role in HVR
function, we compared the 1H-15N HSQC NMR spectra of
K-Ras4B1-188 and K-Ras4B1-166 in the GDP- and GTP-
bound states (Fig. 2, A and C). Spectral comparison revealed
residues with significant CSPs caused by HVR. The residues
were mapped on the crystal structures of GDP- and GTP-
bound K-Ras catalytic domains (Fig. 2, B and D). Most of
the changes occur in the Switch I and effector binding re-
gions, b2, and in the C-terminal helix, a5. This suggests
that in the GDP-bound state, the C-terminal HVR interacts
extensively with the catalytic domain. An additional indica-
tion of the interaction between the HVR and the GDP-bound
catalytic domain is the observation of slow conformational
exchange between two different states in K-Ras4B1-188-
GDP in the catalytic domain residue G60 and the HVR
residue G174. The slow exchange in the G60 position is
dependent on the presence of the HVR because only a single
peak for G60 is found in the spectrum of truncated
K-Ras4B1-166-GDP. The rest of the HVR signals are de-
tected as single peaks, which is possibly indicative of fast
exchange. When K-Ras4B is GTP-g-S bound, only veryfew changes are observed in the Switch I and effector bind-
ing regions (I36) and in the adjacent N-terminal portion
(S17 and A18).
To further validate our NMR data, we analyzed the effect
of HVR mutations K180A and K182A on the structure of
the catalytic domain. We reasoned that any change in the
structure of HVR should have an effect on the catalytic
domain of K-Ras4B-GDP if the HVR is indeed sequestered
by the Switch I region. HVR mutations K180A and K182A
caused significant CSPs in the Switch I region of K-Ras4B-
GDP. We performed additional 15N HSQC NMR experi-
ments on HVR point mutants, K180A and K182A, in the
GDP-bound state. CSPs were obtained by comparing the
spectra of the K180A (Fig. 3, A and B) and K182A
(Fig. 3, C and D) mutants with the spectrum of wild-type
K-Ras4B1-188-GDP. We observed significant CSPs in the
Switch I region (residues 30–38) and a1 helix (residues
16–26). In both cases, E37 exhibited the highest CSPs, sug-
gesting that these lysine residues are involved in HVR
sequestration by the catalytic domain. The K180 and
K182 residues are relatively far removed from the HVR
attachment to the catalytic domain and are expected to
have a reduced effect on HVR sequestration. An HVR mu-
tation in the region closer to the catalytic domain is antici-
pated to more significantly perturb the chemical shifts in
the catalytic domain than the K180A and K182A mutations.
To test this hypothesis, we prepared K-Ras4B1-188-GDP
bearing a K175A mutation in the HVR (Fig. S1 in the Sup-
porting Material). Comparisons of NMR chemical shift
differences between the mutant and wild-type full-length
proteins revealed larger and more numerous CSPs caused
by the K175A than those caused by the K180A and
K182A mutations. These data suggest that the K175A mu-
tation induces a significant disruption of the HVR-catalytic
domain interaction.
The recently published crystal structures of K-Ras4B
exhibit a helix-5 C-terminal extended by two additional
turns (9). This structure suggests that, due to the extended
helix-5, it would be difficult for the HVR to reach the
effector binding region in the catalytic domain. To address
this issue, we analyzed B-factors for this part of the mole-
cule (Fig. S2). The B-factors for helix-5 are high, suggesting
a high degree of flexibility. To address the possibility that
the HVR may be flexible, we measured 1H-[15N] heteronu-
clear nuclear Overhauser effect (NOEs) for K-Ras4B-GDP
(Fig. 3 E). Most of the structure of the catalytic domain is
rigid with heteronuclear NOEs in the range between 0.8
and 1. Residue H166 exhibits a negative heteronuclear
NOE, suggesting a high degree of disorder. Residues 167–
169 have positive but low heteronuclear NOEs of ~0.5.
G174 has a positive but very low heteronuclear NOE of
0.1 and is in a flexible area. The lysines K175, K176,
K177, K178, K179, and K180 exhibit positive heteronuclear
NOEs approaching 0.8, suggesting a relatively rigid confor-
mation for this part of the molecule. One reason for theBiophysical Journal 109(12) 2602–2613
FIGURE 2 NMR CSPs of residues in the full-
length and truncated K-Ras4B in the GDP-bound
and GTP-bound states by the HVR, and their map-
ping onto crystal structures. Superimpositions of
1H-15N HSQC spectra of (A) full-length K-Ras4B
(blue, 0.78 mM) and truncated K-Ras4B1-166 (red,
1 mM) in the GDP-bound states, and (B) mapping
of the perturbed residues on the structure of the
GDP-bound K-Ras4B catalytic domain; (C) full-
length K-Ras4B (blue, 0.5 mM) and truncated
K-Ras4B1-166 (red, 0.4 mM) in the GTP-g-S-bound
states, and (D) mapping of the perturbed residues
on the catalytic domain structure of GTP-bound
K-Ras4B. (Arrows) Examples of CSPs and their
resonance assignments. New resonances in the
spectrum of full-length K-Ras4B represent the
HVRs (shown in blue). In the structures, the side
chains of residues with statistically significant
CSPs are shown (yellow) and marked with residue
type and number. These experiments were per-
formed using a 900 Mhz Avance Spectrometer
(Bruker Daltonics). To see this figure in color, go
online.
2606 Chavan et al.increased rigidity is binding of these lysines to the catalytic
domain. Residues 181, 182, 183, and 184 have heteronu-
clear NOEs suggestive of high flexibility.K-Ras4B HVR analogs interact with K-Ras1-166
with high affinity
High affinity interactions of HVR with the catalytic domain
of K-Ras4B are more likely to play a significant functional
role than transient low affinity binding. To determine the af-
finity of HVR for GDP- and GTP-g-S-loaded K-Ras4B1-166,
we generated a K-Ras4B HVR synthetic analog (kR-4B-17:
Ac-KEKLNSKDGKKKKKKSKTK-NH2). MST (37,38) re-
vealed that the peptide interacts better with GDP- than with
GTP-g-S-bound K-Ras4B1-166, with dissociation constants,
KD, of 250.0 5 33.4 nM and 18.6 5 0.9 mM, respectively
(Fig. 4 A). The interaction appeared sequence-specific. Sub-
stitution of just one residue, D173, with proline (kR-4B-28:
Ac-KEKLNSKPGKKKKKKSKTK-NH2) abolished the in
teraction. The D173P mutation was selected because of its
likely disruptive effect on any secondary structure elements
that might form in the N-terminal portion of the HVR to
stabilize its interaction with the catalytic domain. In addi-
tion, phosphorylation of S181 (kR-4B-26: Ac-KEKLN
SKDGKKKKKKS(PO4)KTK-NH2), a posttranslational
modification known to regulate K-Ras4B interaction with
calmodulin (39), prevents binding of HVR to the catalyticBiophysical Journal 109(12) 2602–2613domain. To determine whether membrane interaction
prevents the HVR from binding the G-domain, we per-
formed binding studies for the lipidated K-Ras4B HVR
analog (kR-4B-1: Ac-KEKLNSKDGKKKKKKSKTKK-ε-
Pal-NH2) in the presence of membrane-mimicking nano-
disks (Fig. 4 B). Membrane anchoring of the HVR analog
had no significant effects on its interaction with
K-Ras4B1-166-GDP (KD ¼ 230.0 5 22.1 nM).
Next, using NMR, we addressed the question of speci-
ficity of high affinity peptide binding to the catalytic domain
of K-Ras4B-GDP. We added an excess (1.5 molar equiva-
lents) of the HVR peptide to 15N-enriched K-Ras4B1-166-
GDP and compared its 15N HSQC spectra with and without
the peptide. The results highlight resonances for D30, Y32,
I36 and T158, and four side chains (Fig. 5 A). The CSPs
induced by the HVR in the full-length and truncated pro-
teins concentrate in the same area, namely the Switch I re-
gion and helix a5. Moreover, comparison of side-chain
resonances in the ε-NH region of the spectra indicates strik-
ing similarities between chemical shifts in K-Ras1-166-GDP
bound to the HVR peptide and in full-length K-Ras4B-GDP.
The similarity of CSPs induced by HVR peptide addition
(Fig. 5 B) and those induced by HVR in the full-length
protein (Fig. 5 C) indicates the specificity of HVR to
the catalytic domain of K-Ras4B-GDP. To observe the
impact of membrane phospholipids on HVR binding to
the catalytic domain, we compared 1H-15N HSQC spectra
FIGURE 3 CSPs obtained after comparing
K-Ras4B-GDP K180A and K182A mutants. Over-
lays of 15N-HSQC NMR spectra of full-length,
wild-type K-Ras4B-GDP protein (blue) and (A)
K180A and (C) K182A mutants of K-Ras4B-
GDP (red). The CSPs measured from the spectra
for (B) K180A and (D) K182A mutants. (Arrows)
Examples of chemical shift changes. (Red horizon-
tal line in the graph) Sum of average CSP with
1 SD. The names of residues exhibiting statistically
significant (above the line) CSPs are marked.
(E) 1H-[15N] heteronuclear NOEs for full-length
K-Ras4B-GDP. To see this figure in color, go
online.
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absence of nanodisks (Fig. 5 D). We used DPPC nanodisks
at the 1:100 (protein/lipid) molar ratio. Our initial hypothe-
sis is that the HVR in K-Ras4B-GDP does not extensively
interact with the membrane. Nanodisks induced chemical
shift changes in E3, the Switch I region (G12, V29),
the effector binding region (D30, S32, E33), Switch II
(I46, C51, D54, G60), K147, and the HVR (G174, K175,
K176, and K177). While HVR partly participates in
K-Ras4B1-188-GDP binding the phospholipids, the catalytic
domain is a major contributor. Interestingly, resonances for
K178, K179, and K180 did not change upon addition of
phospholipids, suggesting that these lysines are not involved
in membrane binding when K-Ras4B is in the GDP-bound
state. Thus, the membrane only partly competes with the
sequestered HVR in K-Ras4B-GDP. In contrast, an overlayof 15N HSQC spectra of K-Ras4B-GTP-g-S in the presence
and absence of DPPC nanodisks shown in Fig. 5 E indicates
CSPs induced predominantly in the HVR. In addition, bind-
ing studies utilizing nanodisks as membrane mimetics have
shown that K-Ras4B-GTP-g-S has a higher affinity for
phospholipid bilayers than K-Ras4B-GDP (Fig. S3).Atomic details of the HVR interaction with the
catalytic domain
NMR-based structural determination of full-length K-Ras
was difficult due to significant resonance line-broadening
caused by conformational exchanges. To obtain structural
details of the HVR interaction with the GDP-bound catalytic
domain, we performed all-atom MD simulations (30,33) on
K-Ras4B1-185 and K-Ras4B1-166 in an aqueous environment.Biophysical Journal 109(12) 2602–2613
FIGURE 4 Analogs of K-Ras4B HVR interact
with recombinant truncated K-Ras4B1-166. (A)
The interaction was characterized using recombi-
nant K-Ras4B1-166 that was labeled on Cys
118
with fluorescein maleimide. GDP-bound and
GTP-g-S-bound proteins have been titrated with a
synthetic HVR analog, the kR-4B-17 peptide,
Ac-KEKLNSKDGKKKKKKSKTK-NH2; its vari
ant kR-4B-28 that had D173P substitution, Ac-
KEKLNSKPGKKKKKKSKTK-NH2; and phospho
rylated analog kR-4B-26, Ac-KEKLNSKDGKKK
KKKS(PO4)KTK-NH2. Addition of kR-4B-17,
but not of the control or phosphorylated analog,
caused a significant change in the protein thermo-
phoretic mobility that allowed for determination of KD. (B) Palmitoylated HVR analog kR-4B-1, Ac-KEKLNSKDGKKKKKKSKTKK-ε-Pal-NH2 showed
high affinity binding to GDP-loaded K-Ras4B1-166 in the presence of membrane-mimicking nanodisks. To see this figure in color, go online.
2608 Chavan et al.The crystal structures of the GDP- and GTP-bound catalytic
domains (Fig. S4 A) were used to generate four different
initial configurations based on the NMR CSP data
(Fig. S4, B and C). During the initial generation, the HVR
chain folded over residues presenting highly perturbed
NMR chemical shifts (Fig. 2). Four independent simulations
for each nucleotide with the full-length as well as truncated
Ras proteins as controls were carried out. Three of the four
configurations retain the HVR on the catalytic domain of
K-Ras4B-GDP, while only two out of four retain the HVR
on K-Ras4B-GTP, marginally interacting with the catalytic
domain (Fig. 6). We calculated the interaction energy of
the HVR with the catalytic domain to determine the best
candidate for the structural model of folded HVRBiophysical Journal 109(12) 2602–2613(Fig. S5). The interactions of the HVR with the catalytic
domain are mainly driven by electrostatics and reveal stron-
ger attraction in K-Ras4B-GDP as compared to the GTP
counterpart. Based on these data, we designated the config-
urations 2 and 3 of K-Ras4B-GDP and the configurations 3
and 4 of K-Ras4B-GTP as the best model conformations of
HVR interacting with the catalytic domain. We speculate
that these configurations can reflect sampled ensembles of
K-Ras4B conformations in solution for the highly populated
NMR observations.
The catalytic domain is highly conserved during the sim-
ulations, with root-mean-squared deviation (RMSD)<1.0 A˚
relative to the starting point for truncated K-Ras4B1-166
(Fig. S6, A and B). For full-length K-Ras4B1-185, althoughFIGURE 5 Investigation by NMR of interactions
of theHVRwith theGDP-bound state of the catalytic
domain of K-Ras4B. (A) A superimposition of 15N
HSQC spectra of GDP-bound K-Ras4B1-166 in the
absence (blue) and in the presence of 1.5 molar
equivalents of the HVR peptide (red). (Arrows) Ex-
amples ofCSPs. Zoomed-in ε-NH regions in spectral
superimpositions of (B) GDP-bound K-Ras4B1-166
in the absence (blue) and in the presence of 1.5molar
equivalents of the HVR peptide (red) and (C) full-
length GDP-bound K-Ras4B (red, 0.4 mM) and
GDP-bound K-Ras4B1-166 (blue, 1 mM). These ex-
periments were performed using a 600 Mhz Avance
Spectrometer (BrukerDaltonics). The chemical shift
changes induced by HVR in the full-length protein
are more numerous than those caused by the HVR
peptide in the catalytic domain of K-Ras4B-GDP.
The reason for this may be the higher effective
concentration of HVR in the full-length protein,
as compared to peptide titration into a solu-
tion containing the catalytic domain. Overlays of
15N HSQC spectra of (D) 0.4 mM full-length
K-Ras4B-GDP (red) and 0.4 mM K-Ras4B-GDP
in the presence of a 100-fold molar access of
DPPC lipids (blue) and (E) of 0.37 mM full-length
K-Ras4B-GTP-g-S (red) and 0.37 mM K-Ras4B-
GTP-g-S in the presence of a 100-fold molar access
of DPPC lipids (blue). CSPs are marked. To see this
figure in color, go online.
FIGURE 6 Computational modeling of the HVR. Relaxed structures of full-length K-Ras4B in the aqueous environments. Ensembles of HVR structures
sampled at each 10 ns simulation are shown on the averaged catalytic domain structures of K-Ras4B over 100 ns MD simulations in the (A) GDP-bound and
(B) GTP-bound states. In the catalytic domain, the a-helix (gray) and b-sheet (yellow) secondary structures are shown; (blue) HVR. To see this figure in color,
go online.
K-Ras HVR Binding to Ras Active Site 2609the overall conformation of the catalytic domain is pre-
served with RMSD <1.5 A˚, there are subtle structural rear-
rangements in the effector binding lobe, including Switch I,
Switch II, helices a1 and a5, and b1–3 strands in K-Ras4B-
GDP, and Switch I, Switch II, and helix a1 in K-Ras4B-GTP
(Fig. S6, D and E). Further, large structural differences are
observed when the catalytic domains are compared between
the full-length GDP- and GTP-bound states, in contrast to
the truncated states (Fig. S6, C and F). These differences
are expected to favor HVR binding to GDP-bound as
compared to GTP-bound Ras. This is in agreement with
the NMR and MST data showing that the HVR is seques-
tered by the catalytic domain in GDP-bound K-Ras4B, but
is released in the GTP-bound state. In both GDP- and
GTP-bound states, the highly populated HVR conforma-
tions are mainly coiled chains (Fig. S7), although a transient
b-sheet extended over the b2-strand can be formed by the
HVR of configuration 3 of K-Ras4B-GDP (Fig. S8). In
the GDP-bound state, the N-terminal portion of the HVR
is relatively rigid, attaching tightly to the catalytic domain,
while the C-terminal portion of the HVR is rather flexible
(Fig. 6). For configuration 2 of K-Ras4B-GDP, the tighter
interaction of the coiled HVR with the catalytic domain is
likely attributed to salt-bridge formations. This conforma-
tion predicts that HVR residues K172 and K175 form salt
bridges with E3 and E37, respectively. Other lysines in the
polybasic region (residues 175–180) also form salt bridges
with D38 in Switch I and E62 and E63 in Switch II regions,strongly sequestrating the HVR to the effector lobe. For
configuration 3 of K-Ras4B-GDP, the HVR is observed to
populate a b-sheet with higher occupancy of a b-strand
conformation in the S171- D173 region, forming an antipar-
allel b-sheet motif. HVR residue D173 forms a salt bridge
with K42, stabilizing the HVR b-sheet. The polybasic ly-
sines also form salt bridges with E37, D38, and D54. Lateral
shifts in the HVR b-strand location are possible. Although
the upstream-terminal portions of both coiled and stranded
HVRs interact with different regions of catalytic domain,
their polybasic lysines commonly interact with the Switch
I and b2 regions. This b2-strand is in the effector interaction
site, with the HVR antiparallel b-sheet mimicking the com-
mon Ras effector-binding motif. To complement the NMR
CSPs, we calculated the combined CSPs (40,41), mapping
them over K-Ras4B1-166 (Fig. S9, A and B). In the GDP-
bound state, many residues exhibit perturbations, especially
in the Switch I and effector binding regions, in agreement
with the NMR results (Fig. S9, C and D). In the GTP-bound
state, fewer residues are perturbed, suggesting loose HVR-
catalytic domain interaction. Perturbations of thermal fluc-
tuations during the simulations for K-Ras4B with respect
to K-Ras4B1-166 also point to residues in b2, including the
effector-binding region and Switch I and II, as HVR binding
sites (Fig. S9, E and F). Interactions between the HVR and
the GDP-bound catalytic domain are transient, suggesting
that multiple possible modes of interactions are common.
NMR experiments and computational analysis were doneBiophysical Journal 109(12) 2602–2613
2610 Chavan et al.in the absence of C-terminal lipidation, while one HVR pep-
tide was modified with a lipid group for binding affinity
studies, which suggests a stable association.The interaction of HVR with the catalytic domain
prevents low affinity Raf1 binding to K-Ras4B-
GDP but has a small effect on GEF-catalyzed
nucleotide exchange
Ras-dependent activation of Raf-1 is initiated when its Ras-
binding domain (Raf-1 RBD) interacts with the effector re-
gion of Ras-GTP with nanomolar affinity. Raf-1 also binds
to Ras-GDP with an affinity that is 100-fold lower than
that for Ras-GTP (42). The low affinity binding to Ras-
GDP may be relevant in cells because in the full-length
Raf-1 protein, the cysteine-rich domain also binds Ras in
a nucleotide-independent manner (43). The HVR interacts
with the catalytic domain through the effector binding
site. To investigate the impact of HVR sequestration on
Raf-1 interaction, we performed the Raf-1 binding assay
(35) with the full-length and truncated forms of K-Ras4B-
GTP-g-S and K-Ras4B-GDP. The comparison of Raf-1
binding was done with K-Ras4B1-166-GTP-g-S against
K-Ras4B1-188-GTP-g-S and with K-Ras4B1-166-GDP
against K-Ras4B1-188-GDP (Fig. 7 A). Our results demon-
strate that full-length K-Ras4B-GDP binds Raf-1 RBD
with 52% efficiency when compared to the catalytic domain
of K-Ras4B-GDP. The low efficiency of Raf RBD binding
to K-Ras4B1-188-GDP compared to K-Ras4B1-166-GDP
suggests that the HVR interferes with the effector binding
to the catalytic domain. At the same time, we observed an
~27% increase in the efficiency of Raf-1 RBD binding to
GTP-g-S loaded full-length K-Ras4B compared to the cata-
lytic domain, suggesting that the HVR can interact with Raf.
Thus, our findings suggest that K-Ras4B in the GDP-bound
state is autoinhibited by its HVR. To address the question of
whether autoinhibited K-Ras4B can be activated by GEFs,
we evaluated the influence of HVR analogs on nucleotide
exchange catalyzed by the GEF SOS1 using K-Ras4B1-166
loaded with the fluorogenic GDP analog MANT-GDP. The
addition of 570 nM synthetic HVR analog increased the
half-time (T1/2) of the SOS1-catalyzed nucleotide exchange
from 5905 20 s to 7805 25 s. (Fig. 7 B). Further increase
in the HVR analog concentration up to 14 mM did not
improve the degree of nucleotide exchange inhibition, sug-
gesting that the modest decrease in exchange rate by 35%
was the maximal achievable effect under the conditions
used. Our results demonstrate that the autoinhibited form
of K-Ras4B can be activated by a GEF, albeit to a lesser
extent than K-Ras4B without its HVR. The overlap in the
HVR binding interface of K-Ras4B with that of GEFs is
significantly lesser than with Raf. For the modeled Ras/
effector complexes reconstituted from the crystal structures,
the overlapped surface areas in the HVR binding interface by
the effectors are 332.7 A˚2 and 289.1 A˚2 for the Raf and GEF,Biophysical Journal 109(12) 2602–2613respectively (Fig. S10). Consistent with the little direct over-
lap in binding surfaces, HVR has only a moderate effect on
nucleotide exchange. It is important to note that HVR
sequestration does not permanently inhibit K-Ras4B,
because it does not prevent its activation by GEFs. The auto-
inhibited state can be reversed upon proper stimulation.DISCUSSION
The paradigm for Ras function states that resting GDP-
bound Ras is activated by GEFs catalyzing GDP exchange
for GTP (44). GTP binding induces a conformational
change in the Switch I and Switch II regions and exposes
the effector interaction site in Ras (45). Ras effectors,
such as Raf kinase, bind Ras-GTP with a higher affinity
than Ras-GDP and this allows initiation of signaling.
Signaling proceeds until Ras hydrolyzes GTP to GDP
with the help of GTPase activating proteins. Subsequently,
the low affinity effector-Ras-GDP complex dissociates and
signaling stops. Our results suggest that this model of Ras
function is incomplete. We show that HVR is sequestered
by the GDP-bound catalytic domain of K-Ras4B but is
released in the GTP-bound state. We propose that GDP-
bound K-Ras4B is autoinhibited by its HVR, which dictates
how K-Ras4B is activated, how it is recruited to the plasma
membrane, and how K-Ras4B signaling is initiated and
stopped after GTP hydrolysis. The structural details of the
HVR interaction with the catalytic domain in the GDP-
bound states from the simulations illustrate that the HVR
prefers to interact with the effector binding site in the
effector lobe of the protein. Similarly, the HVR also resides
in the effector lobe side in the GTP-bound state, although
the HVR marginally interacts with the catalytic domain.
The HVR residency on the effector lobe suggests that the
HVR may function as a switch through releasing and retain-
ing the HVR autoinhibition.
Autoinhibition by HVR regulates K-Ras4B interactions
with the plasma membrane phospholipids. HVR is a major
membrane targeting element in Ras GTPases (19). Its
sequestration by the GDP-bound catalytic domain reduces
the affinity of K-Ras4B for the lipid bilayers (Fig. S3),
temporarily discontinuing signaling. A similar nucleotide-
dependent mechanism is employed by Arf and Rac GTPases
to regulate their function at the plasma membrane (46,47).
Concomitantly, HVR sequestration can regulate effector
binding to K-Ras4B. It is remarkable that the K-Ras4B1-166-
HVRb-sheet interface is similar to that of RafRBD.We spec-
ulate that within the HVR ensemble, a preexisting b-strand
conformer selectively binds to the functional site of the
K-Ras4B catalytic domain to extend the b-sheet, a common
interface motif. Consistent with this mode of interaction,
HVR significantly affects binding of GDP-loaded K-Ras4B
to Raf RBD. The markedly less effective binding of Raf
RBD to GDP-bound K-Ras4B1-188 than to GDP-bound
K-Ras4B1-166 suggests that the HVR plays an important
FIGURE 7 HVR binding to the catalytic do-
main reduces the interaction of Raf-1RBD with
full-length K-Ras4B-GDP but not with K-Ras4B-
GTP-g-S and moderately interferes with nucleo-
tide exchange. (A) An RBD pull-down assay was
used to determine the difference in binding of equal
amounts of the catalytic domain and full-length
K-Ras4B in its GTP-g-S and GDP-bound states.
The amount of Raf-1 RBD bound to either
K-Ras4B1-166-GTP-g-S or K-Ras4B1-166-GDP
was assumed to be 100%. Thus, RBD binding of
full-length K-Ras4B1-188-GTP-g-S was 127.8 5
2% when normalized to K-Ras4B1-166-GTP-g-S
binding. However, RBD binding of K-Ras4B1-188-
GDP was only 55.2 5 3.1% when compared to
K-Ras4B1-166-GDP binding. Thus, the full-length
K-Ras4B1-188-GTP-g-S interacted with Raf-1
RBD with higher efficiency than with truncated
K-Ras4B1-166-GTP-g-S (p < 0.001). The interac-
tion of Raf-1 RBD with full-length K-Ras4B1-188-
GDP was less efficient than with truncated
K-Ras4B1-166-GDP (p < 0.001). (B) MANT-
GDP-bound recombinant truncated K-Ras4B1-166
(0.3 mM) was incubated with 200 mM GDP in the
presence of 0.6 mM SOS1. The rate of fluorescence
decrease was slower in the presence of HVR analog
(red) compared to the control (black), but inhibi-
tion of exchange appeared incomplete when
compared to the rate of uncatalyzed exchange
(blue). To see this figure in color, go online.
K-Ras HVR Binding to Ras Active Site 2611role in fencing off premature signaling from the GDP-bound
protein. At the same time, the presence of HVR in full-length
K-Ras4B-GTP-g-S increases the interaction efficiency with
Raf RBD, implying that there is a possible binding site for
HVR in Raf. Thus, HVR in both the sequestered and released
conformations can regulate signaling through Raf, and other
effectors, such as PI3K. Importantly, the HVR in K-Ras4B-
GTP provides the major binding site for calmodulin (36); in
the GDP-bound state, the HVR is unavailable to interact
with calmodulin due to its sequestration by the catalytic
domain.
It is difficult to speculate whether HVRs similarly auto-
inhibit other Ras GTPases. Ras isoforms differ predomi-
nantly in their HVR regions and these differences havefunctional implications (48,49). In H-Ras, the HVR affects
backbone dynamics of the catalytic domain. However,
high affinity sequestration was not observed (50). HVRs
of other Ras isoforms may also regulate effector binding
and/or GDP/GTP exchange. Domain swapping has shown
that H-Ras, but not N-Ras HVR, determines the invasive/
migratory signaling program in breast tumor cells, inde-
pendent of differences in lipidation between the two
HVRs (51).
It is also unclear whether the newly discovered autoinhi-
bition mechanism plays a role in K-Ras-mediated oncogen-
esis. Our finding that an oncogenic mutation in K-Ras
affects the interaction of HVR with the active site allows
us to speculate that oncogenic mutations may allostericallyBiophysical Journal 109(12) 2602–2613
2612 Chavan et al.modulate HVR-binding affinity. Our recent results suggest
that this is indeed the case, at least for those mutations
that we inspected, i.e., G12C, G12D, G12V, G13D, Q61H,
and R164Q, and for E37K orthosterically (52). This partic-
ularly holds for GTP-bound K-Ras4B.
The role of HVR in K-Ras4B-induced oncogenesis
remains controversial, with reports supporting both highly
significant and more subtle effects of HVR mutations on
K-Ras4B G12V-dependent cancer transformation (18,53).
Detailed studies of HVR interactions in different Ras
mutants may uncover additional modes of modulation of
oncogenic activity.
Finally, the high affinity interaction of HVR with the
active site of K-Ras4B suggests that targeting this surface
with synthetic inhibitors is feasible. Optimization of com-
pounds that bind at the HVR-catalytic domain interface
and promote K-Ras4B autoinhibition is a potentially prom-
ising approach for development of potent inhibitors of so-far
undruggable Ras (12). However, drug resistance may still be
expected to arise and a combinatorial drug cocktail regime
(13) will still be required.SUPPORTING MATERIAL
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